Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Recently published
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Loss of Fas signaling in fibroblasts impairs homeostatic fibrosis resolution and promotes persistent pulmonary fibrosis
Elizabeth F. Redente, … , Max A. Seibold, David W.H. Riches
Elizabeth F. Redente, … , Max A. Seibold, David W.H. Riches
Published December 8, 2020
Citation Information: JCI Insight. 2021;6(1):e141618. https://doi.org/10.1172/jci.insight.141618.
View: Text | PDF
Research Article Pulmonology

Loss of Fas signaling in fibroblasts impairs homeostatic fibrosis resolution and promotes persistent pulmonary fibrosis

  • Text
  • PDF
Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible fibrotic disease of the distal lung alveoli that culminates in respiratory failure and reduced lifespan. Unlike normal lung repair in response to injury, IPF is associated with the accumulation and persistence of fibroblasts and myofibroblasts, as well as continued production of collagen and other extracellular matrix (ECM) components. Prior in vitro studies have led to the hypothesis that the development of resistance to Fas-induced apoptosis by lung fibroblasts and myofibroblasts contributes to their accumulation in the distal lung tissues of IPF patients. Here, we test this hypothesis in vivo in the resolving model of bleomycin-induced pulmonary fibrosis in mice. Using genetic loss-of-function approaches to inhibit Fas signaling in fibroblasts, potentially novel flow cytometry strategies to quantify lung fibroblast subsets, and transcriptional profiling of lung fibroblasts by bulk and single cell RNA sequencing, we show that Fas is necessary for lung fibroblast apoptosis during homeostatic resolution of bleomycin-induced pulmonary fibrosis in vivo. Furthermore, we show that loss of Fas signaling leads to the persistence and continued profibrotic functions of lung fibroblasts. Our studies provide insights into the mechanisms that contribute to fibroblast survival, persistence, and continued ECM deposition in the context of IPF and how failure to undergo Fas-induced apoptosis impairs fibrosis resolution.

Authors

Elizabeth F. Redente, Sangeeta Chakraborty, Satria Sajuthi, Bart P. Black, Ben L. Edelman, Max A. Seibold, David W.H. Riches

×

Figure 9

scRNA-seq reveals distinct fibroblast populations in naive and fibrotic lungs.

Options: View larger image (or click on image) Download as PowerPoint
scRNA-seq reveals distinct fibroblast populations in naive and fibrotic ...
(A) UMAP plot of all samples and the identified population clusters and from Fas-sufficient naive mice 3 and 6 weeks after bleomycin. (B) Violin plots showing genes highly associated with Wnt2+ Lipofibroblasts (clusters 1 and 2). (C) Violin plots showing genes highly associated with Col14a1+ mesenchymal alveolar niche cells (MANCs) (clusters 3 and 4). (D) Violin plots showing genes highly associated with profibrotic fibroblasts (clusters 5 and 6). O, combined expression of other clusters (clusters 3, 6, 8, 9, 11, 13, 15). (E) Representation of enrichment for GO pathway categories for clusters 1, 2, 3, 4, 5, and 6, a total of 6 weeks after bleomycin. (F) Pseudotime trajectory analysis for 2 scenarios. Violin plots show median. n = 4 pooled mice/group.
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts